TransCode Therapeutics Inc (RNAZ) Quote

NEW PARTNERS 🔥🔥🔥🔥🔥https://www.3i.com/about-us/

TAKE OUT THE ATOMIC BOMB NEWS AND SHOCK THE WORLD RNAZ🔥🔥🔥🔥🔥

RNAZ BACKED BY KING KONG 🔥🔥🔥🔥🔥3i has the power to dispose of and the power to vote the Shares beneficially owned by it, which power may be exercised by 3i Management, the manager and general partner of 3i. Mr. Tarlow, as the manager of 3i Management, has shared power to vote and/or dispose of the Shares beneficially owned by each of 3i and 3i Management. Mr. Tarlow does not directly own the Shares. By reason of the provisions of Rule 13d-3 of the Act, Mr. Tarlow may be deemed to beneficially own the Shares beneficially owned by 3i and 3i Management, and 3i Management may be deemed to beneficially own the Shares beneficially owned by 3i.

Can’t open. What does it show or say?

BIG NEWS MONDAY MORNING🔥🔥🔥🔥🔥🔥

I’ll crack a beer for AH GREEN YAAAY! Lol

POWERFUL NEWS FROM THE UK 🔥🔥🔥
https://www.3i.com/

800K in volume before close now over 6 million shares in aftermarket volume…..

SOUND ALL ALARMS SOUND ALL ALARMS BREAKTHROUGH🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥

3i management and Mr. Harlow

What did they talk about?

Just saw it on cnbc

Flying on air…..

A tremendous amount of Aftermarket volume compared to volume all day….. hmmm

30 cents to zero or 30 cents to 20$ there is a lot of money to be made if it goes up. Maybe dna will buy them. I don’t care if it’s 5$ a share my 500000 shares will look pretty in my account if I lose then tax write off. 150k loss or 2.5 million made

Management never materialized an event, it’s a garbage scam

The garbage can closed and everyone is dumping the garbage

Everyone dumped their shares broski

Why you think it’s a garbage?

What happened, couple of hours ago you were so gaga about it?

Everyone is dumping the garbage , nobody believes in this garbage

No sign of life even after garbage can closed its lid

Go on shorts collapse this piece of garbage to 0

Did CEO Fitzgerald ever materialize an event??

The dream team collapse
election of four (4) directors, Philippe P. Calais, PharmD, PhD, Thomas A. Fitzgerald, Erik Manting, PhD, and Magda Marquet, PhD,

What ever happened to this garbage
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
January 29 2024 - 8:30AM


Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced a co-research agreement with Debiopharm, a privately-owned Swiss-based, global biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases. The collaboration will explore combining TransCode’s proprietary TTX delivery platform with Debiopharm’s expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer.
TransCode’s TTX platform will serve as a backbone for development of antigen-selective nucleic acid delivery vehicles for targeted cancer therapeutics. TransCode has developed and tested the TTX platform for the delivery of various nucleic acid therapeutics to cancer cells, including small interfering RNAs, antisense oligonucleotides, immunostimulatory oligonucleotides, mRNA, and genome-editing ribonucleoprotein complexes (CRISPR). TransCode’s lead therapeutic candidate, TTX-MC138, designed to use antisense technology to treat metastatic cancer, is being evaluated in an early-stage clinical trial. As part of the collaboration, TransCode will combine its TTX delivery platform with Debiopharm’s proprietary technologies to generate constructs designed to provide targeted mRNA delivery to cancer cells. Under the agreement, these constructs will be tested both in cancer cells and in tumor-bearing animals.

Specializing in the manufacturing and development of oncology and antibiotic therapies, Debiopharm entered this research collaboration to test the development of new targeted nucleic acid delivery modalities. Debiopharm’s ongoing quest towards developing highly innovative drug delivery methods is based on the recognition that novel targeted medicines hold the potential to revolutionize cancer research and treatment by improving precision, efficacy, safety, and the overall therapeutic outcome for cancer patients. The company hopes that future advancements could usher in a new era of more effective and personalized cancer therapies.

Frédéric Lévy, Debiopharm’s Chief Scientific Officer, commented, “We believe that TransCode’s TTX platform has the potential to bring about significant advances in drug delivery for cancer because of its versatility in terms of the payloads it can be used to deliver, including not only a wide array of nucleic acids but also peptides and proteins.”

Zdravka Medarova, TransCode’s Chief Scientific Officer, added, “Debiopharm is a global player in the field of cancer therapeutics, known for the development of standard of care drugs for the treatment of various types of cancer. For TransCode, being able to collaborate with Debiopharm on an innovative project with the potential impact of targeted nucleic acid-based cancer therapeutics, represents a pivotal point for our company.”

Financial terms were not disclosed.

About TransCode Therapeuti

Very impressive garbage
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
February 20 2024 - 8:00AM


Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported publication of United States Patent Application titled, “Nanoparticles and Template Directed RIG-I Agonist Precursor Compositions and Uses Thereof For Cancer Therapy“ (Pub. No.: US 2024/0042070 A1; Pub. Date: February 8, 2024).
The application describes compositions and methods to treat cancer using a novel class of immunotherapy inspired by the innate immunity of mammalian cells against microbes. This novel type of immunotherapy targets molecules called retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs). RLRs are key RNA sensors that can be activated for the treatment of cancer using synthetic RNAs that mimic viral infection, directing the immune response against cancer. There is no assurance that any patent will issue from this application.

TransCode’s RIG-I agonist precursor comprises single-stranded 5’-uncapped biphosphate or triphosphate oligonucleotides having a sequence complementary to an endogenous microRNA. The precursor may be carried by a nanoparticle such as TransCode’s TTX delivery technology and may include a radiolabel for imaging or therapy. It is designed to activate the immune system against tumor cells with high specificity potentially resulting in effective treatment of multiple primary, metastatic, and recurrent cancers. What is novel about TransCode’s approach is the capacity to recruit pattern recognition receptors (PRRs), such as RIG-I, in a tumor-selective manner which TransCode believes is critical for clinical applications.

“TransCode’s tumor-selective RIG-I agonists could enable this novel immunotherapy against cancer by triggering the immune system to attack the specific tumor while sparing healthy tissue,” commented Zdravka Medarova, Ph.D., Chief Science Officer at TransCode. “Further selectivity against cancer may be achievable by linking RIG-I agonists to TransCode’s TTX delivery platform. This linkage mechanism is currently being studied in a first-in-human microdose clinical trial with a radiolabeled version of TransCode’s lead therapeutic candidate, TTX-MC138. TTX-MC138 consists of an iron oxide nanocarrier conjugated to a nucleic acid specifically designed to inhibit the oncogenic RNA, microRNA-10b. Preliminary data indicate that following dosing, radioactivity accumulated in the region of the metastatic lesions, consistent with accumulation of TTX-MC138 in lesions observed in preclinical qualitative studies. Data analysis from the subject dosed in this trial is ongoing and will be included in the final trial report.”

More impressive garbage for all
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
March 11 2024 - 9:00AM


Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported positive proof-of-concept laboratory studies in human cells, advancing its strategic partnership with Akribion Genomics.
Akribion Genomics, a German-based biotechnology start-up, is focused on a CRISPR-derived molecular complex for cancer treatment. TransCode and Akribion are collaborating to develop a technology that combines Akribion’s cell-killing G-dase E, a Class 2 CRISPR nuclease, with TransCode's TTX nucleic acid delivery platform. G-dase E has shown encouraging in vitro results in cells but requires an effective delivery vehicle, such as TTX, to reach intended targets in the body.

Proof-of-concept studies to date suggest that Akribion’s G-dase E ribonucleoprotein complexes could be conjugated to TransCode’s TTX delivery platform, suggesting that the drug candidate could be formulated as intended. These studies also indicate that TTX-G-dase E ribonucleoprotein complexes could be taken up by cancer cells, inducing cancer cell death.

Akribion’s Co-Chief Executive Officer, Lukas Linnig, commented, “We are excited about deepening our relationship with TransCode. Together we have now shown that we can successfully synthesize constructs combining TransCode’s TTX platform and our G-dase E nuclease, demonstrating initial laboratory evidence of efficacy in cancer cells. We look forward to continuing to pursue a combined technology for developing highly targeted drugs to treat cancer.”

Zdravka Medarova, PhD, TransCode Chief Scientific Officer, added, “Establishing proof-of- concept is a critical step in advancing our collaboration. We are fully committed to continuing our joint efforts to developing this technology.”

More garbage
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
April 15 2024 - 9:00AM


Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company’s Investigational New Drug (IND) application and concluded that the company may proceed with its Phase 1/2 multicenter, open-label, dose-escalation and dose-expansion study of its lead therapeutic candidate, TTX-MC138, in patients with advanced solid tumors.
“We are thrilled to have obtained FDA authorization to advance TTX-MC138 into the clinic. FDA’s clearance of our IND application represents a significant milestone for our company,” commented Sue Duggan, Senior Vice President, Operations, at TransCode. “Activation of the IND opens the door for continued development of TTX-MC138 in the clinical setting. The Phase 1/2 clinical trial is designed to generate critical data to support evaluation of the safety of TTX-MC138 and may provide early evidence of its clinical activity in patients with metastatic disease.”

The Phase 1/2 clinical trial includes an initial dose-escalation phase followed by a dose-expansion phase. The dose-escalation portion of the trial is designed to include patients with a variety of metastatic solid cancers. The primary objective of this phase is to evaluate the safety and tolerability of escalating dose levels of TTX-MC138. In the dose-expansion phase, certain tumor types will be evaluated based on preliminary results from the dose-escalation phase. The primary objective of the dose-expansion phase is to further evaluate safety as well as tolerability and anti-tumor activity of TTX-MC138 in cancer patients.

The company believes that TTX-MC138 has the potential to positively affect patient outcomes in a range of cancers, including breast, pancreatic, ovarian, colon, glioblastomas and others. In multiple animal models of cancer, treatment with TTX-MC138 led to statistically significant reductions of metastatic burden and longer animal survival relative to animals given control treatments. Successful clinical development of TTX-MC138 potentially represents a novel solution for patients with metastatic cancer.

All trash TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
May 29 2024 - 9:15AM


Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced new preliminary data from its Phase 0 clinical trial with radiolabeled TTX-MC138 suggesting anti-tumor activity.
New results from the patient dosed in this trial indicate that a microdose of radiolabeled TTX-MC138 resulted in significant inhibition of the drug candidate’s molecular target, miRNA-10b, in the patient’s blood. Specifically, after injection, the amount of miR-10b in the patient’s blood was significantly reduced compared to levels prior to administration of radiolabeled TTX-MC138, reaching a reduction of 66% at 24 hours following dosing. “We believe these data are important given that in several animal models, miRNA-10b inhibition by TTX-MC138 resulted in complete regressions of metastatic disease,” stated Zdravka Medarova, PhD, Chief Scientific Officer at TransCode. These data support TransCode’s belief that clinical development of TTX-MC138 has the potential for clinical benefit in patients with metastatic cancer.

In addition, the study also quantified the amount of drug candidate delivered to metastatic lesions, providing further evidence that TTX-MC138 accumulated in metastatic tumors. The increase of radioactive lesion-to-blood ratios suggests that circulating TTX-MC138 is actively taken up by the cancerous tissue.

The microdose of radiolabeled TTX-MC138 was well tolerated with no adverse events observed.

“These new data suggest that TTX-MC138 not only inhibits the miRNA-10b target but is pharmacodynamically active at a single microdose in the patient’s serum, supporting continued clinical development of TTX-MC138 for the treatment of multiple metastatic cancers in the planned Phase 1 clinical study. This could indicate a much broader therapeutic window than had previously been expected,” said Dr. Daniel Vlock, TransCode’s Chief Medical Officer.

Full data analysis is ongoing and will be included in the final study report.

What happened TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
March 11 2024 - 9:00AM


Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported positive proof-of-concept laboratory studies in human cells, advancing its strategic partnership with Akribion Genomics.
Akribion Genomics, a German-based biotechnology start-up, is focused on a CRISPR-derived molecular complex for cancer treatment. TransCode and Akribion are collaborating to develop a technology that combines Akribion’s cell-killing G-dase E, a Class 2 CRISPR nuclease, with TransCode's TTX nucleic acid delivery platform. G-dase E has shown encouraging in vitro results in cells but requires an effective delivery vehicle, such as TTX, to reach intended targets in the body.

Proof-of-concept studies to date suggest that Akribion’s G-dase E ribonucleoprotein complexes could be conjugated to TransCode’s TTX delivery platform, suggesting that the drug candidate could be formulated as intended. These studies also indicate that TTX-G-dase E ribonucleoprotein complexes could be taken up by cancer cells, inducing cancer cell death.

Akribion’s Co-Chief Executive Officer, Lukas Linnig, commented, “We are excited about deepening our relationship with TransCode. Together we have now shown that we can successfully synthesize constructs combining TransCode’s TTX platform and our G-dase E nuclease, demonstrating initial laboratory evidence of efficacy in cancer cells. We look forward to continuing to pursue a combined technology for developing highly targeted drugs to treat cancer.”

Zdravka Medarova, PhD, TransCode Chief Scientific Officer, added, “Establishing proof-of- concept is a critical step in advancing our collaboration. We are fully committed to continuing our joint efforts to developing this technology.”

It’s closed now what?? Reversal in the works!! This is a complete shit show

These clowns have the cure to burnt potatoes it’s all a scam sham

Management should all be jailed for fraudulent activities, These clowns never materialized an event, they reversed and shat on everything that moves

Hard to believe company was worth 200$ a share last year

Where is NIH Grant??

What results?? This clown company buried its holder alive... you can see the beautiful results with pps

Get it all out Meta I picked up 500k of shares down here looks like my retirement package will see after results come out.

Go CEO Fitzgerald go drive this scam to the ground and screw all investors shareholders and the terminally ill cancer patients you dirty rat trash garbage

Where are you hiding now you dirty rat scam CEO scumbag Fitzgerald and all management, hell is coming your way from screwing the terminally ill cancer patients world wide

The rat Fitzgerald scumbag scam artist screwed investors all his career while he pocketing millions in investors$$$

CEO Fitzgerald loves to screw his shareholders, investors, believers and all terminally ill cancer patients with this scam hoax all his career

Y'all enjoy screwing investors RNAZ Management Mr CEO Fitzgerald Hell has a beautiful surprise for scumbags like you dirty rat bastard, You enjoy pocketing investors $$$ and screwing the terminally ill cancer patients

They screwed all terminally ill cancer patients with this scam, they screwed all believers, they screwed all shareholder, have no fear boys and girls hell is where they all belong, God bless to all

I smell the dirty rat bastards in management screwing investors all their careers, hell is where they all belong, Dirty rat Fitzgerald will rot in hell for lying to all investors with this scam

CEO you better wake up and take out the news you dirty rat bastard, you screwed all believers and now you must swimm in rats vomit in hell where you belong

Management will all rot in hell for screwing the terminally ill cancer patients,

The dirty rats bastards in management screwed us all, where is TTX-MC138 you dirty rat scumbags of the earth

Need to put this CEO on the electric chair for screwing shareholders, investors and all terminally ill cancer patients worldwide MoFo, We will all take you to hell you dirty rat bastard

Plata o plomo Mr CEO Make sure of that, This drug needs to get to Terminally Ill cancer patients MoFo, You just can't screw us all and walk on a strait line, hell is where you belong